Literature DB >> 2721544

Effects of buprenorphine on motor activity of the sphincter of Oddi in man.

J C Cuer1, M Dapoigny, S Ajmi, J L Larpent, B Lunaud, C Ferrier, G Bommelaer.   

Abstract

Buprenorphine, (Temgesic), a N-cyclopropylmethyl derivative of oripavine, is both an agonist and antagonist of morphine. Its effect on the motility of the sphincter of Oddi (SO) in humans have been investigated by endoscopic manometry (EM). Buprenorphine leads to a significant decrease in the amplitude of SO contraction waves without altering other parameters. Thus, it has no morphine-like effect on SO motility, but it does act like a partial antagonist of morphine in reducing the amplitude of SO contraction waves.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2721544     DOI： 10.1007/BF00609196

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  7 in total

Review 1.  [Perendoscopic biliary manometry].

Authors:  J C Cuer; M Dapoigny; G Bommelaer
Journal:  Gastroenterol Clin Biol       Date:  1988-05

2.  Manometric study of the sphincter of Oddi in patients with and without common bile duct stones.

Authors:  E De Masi; E Corazziari; F I Habib; B Fontana; V Gatti; G F Fegiz; A Torsoli
Journal:  Gut       Date:  1984-03       Impact factor: 23.059

3.  Sphincter of Oddi motor activity: a comparison between patients with common bile duct stones and controls.

Authors:  J Toouli; J E Geenen; W J Hogan; W J Dodds; R C Arndorfer
Journal:  Gastroenterology       Date:  1982-01       Impact factor: 22.682

4.  Pressure measurements in the biliary and pancreatic duct systems in controls and in patients with gallstones, previous cholecystectomy, or common bile duct stones.

Authors:  A Csendes; A Kruse; P Funch-Jensen; M J Oster; J Ornsholt; E Amdrup
Journal:  Gastroenterology       Date:  1979-12       Impact factor: 22.682

5.  Buprenorphine: a new potent long-acting synthetic analgesic. Comparison with morphine.

Authors:  J W Downing; W P Leary; E S White
Journal:  Br J Anaesth       Date:  1977-03       Impact factor: 9.166

6.  Pain relief in the post-operative period: a comparative trial of morphine and a new analgesic buprenorphine.

Authors:  B C Hovell; A E Ward
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

7.  Histamine release as the basis for morphine action on bile duct and sphincter of Oddi.

Authors:  S Ehrenpreis; I Kimura; T Kobayashi; M Kimura
Journal:  Life Sci       Date:  1987-04-27       Impact factor: 5.037
  7 in total
  5 in total

1.  [Practical pain control in pediatric oncology. Recommendations of the German Society of Pediatric Oncology and Hematology, the German Association for the Study of Pain, the German Society of Palliative Care, and the Vodafone Institute of Children's Pain Therapy and Palliative Care].

Authors:  B Zernikow; C Schiessl; C Wamsler; G Janssen; N Griessinger; R Fengler; F Nauck
Journal:  Schmerz       Date:  2006-02       Impact factor: 1.107

2.  Influence of spasmolytic analgesics on motility of sphincter of Oddi.

Authors:  G Brandstätter; S Schinzel; H Wurzer
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

Review 3.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

4.  Fentanyl but Not Morphine or Buprenorphine Improves the Severity of Necrotizing Acute Pancreatitis in Rats.

Authors:  Emese Réka Bálint; Gabriella Fűr; Balázs Kui; Zsolt Balla; Eszter Sára Kormányos; Erik Márk Orján; Brigitta Tóth; Gyöngyi Horváth; Edina Szűcs; Sándor Benyhe; Eszter Ducza; Petra Pallagi; József Maléth; Viktória Venglovecz; Péter Hegyi; Lóránd Kiss; Zoltán Rakonczay
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

Review 5.  Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain.

Authors:  Ish K Khanna; Sivaram Pillarisetti
Journal:  J Pain Res       Date:  2015-12-04       Impact factor: 3.133
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.